Revelation Biosciences Completes GMP Manufacture of Gemini Drug
12 Nov 2024 //
BUSINESSWIRE
Revelation Biosciences Reports Q3 2024 Financial Results
08 Nov 2024 //
BUSINESSWIRE
Revelation Biosciences Exercises Warrants For $3.8M Gross Proceeds
21 Aug 2024 //
BUSINESSWIRE
Revelation Biosciences Reports Q2 2024 Financial Results
09 Aug 2024 //
BUSINESSWIRE
Revelation Pharma Expands With Taylors Pharmacy And Key Compounding
09 Jul 2024 //
PR NEWSWIRE
Revelation reports Phase 1 study of Gemini meeting safety endpoint
24 Jun 2024 //
BUSINESSWIRE
Revelation`s Has Completed Dosing of its First in Human Ph 1 Study of Gemini
13 Jun 2024 //
BUSINESSWIRE
Revelation Bio Q1 2024 Financials
10 May 2024 //
BUSINESSWIRE
Revelation Announces FR for the Three and Twelve Months Ended Dec/31/23
22 Mar 2024 //
BUSINESSWIRE
Revelation Biosciences Inc. Gives Oral Presentation
13 Mar 2024 //
BUSINESSWIRE
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation
13 Feb 2024 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
05 Feb 2024 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
01 Feb 2024 //
BUSINESSWIRE
Revelation Biosciences Inc. to Present at The International Conference
30 Jan 2024 //
BUSINESSWIRE
Revelation Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
23 Jan 2024 //
BUSINESSWIRE
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Conference
04 Oct 2023 //
BUSINESSWIRE
Revelation Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
02 Oct 2023 //
BUSINESSWIRE
Revelation Announces Financial Results for Three and Six Months
11 Aug 2023 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting
12 Jun 2023 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Financial Results for the Three Months
22 May 2023 //
BUSINESSWIRE
Revelation Announces Financial Results for December 31, 2022
30 Mar 2023 //
BUSINESSWIRE
Revelation to Participate in a Fireside Chat at the 35th Annual Roth Conference
06 Mar 2023 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
13 Feb 2023 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
09 Feb 2023 //
BUSINESSWIRE
Revelation Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
07 Feb 2023 //
BUSINESSWIRE
Revelation Announces 1-for-35 Reverse Stock Split effective February 1, 2023
31 Jan 2023 //
BUSINESSWIRE
Revelation Announces Mandatory Unit Separation to Occur on January 13, 2023
10 Jan 2023 //
BUSINESSWIRE
Revelation Announces Future Clinical DeveP Plans Based on Recent Biomarker
18 Nov 2022 //
BUSINESSWIRE
Revelation Biosciences Inc. Announces Financial Results for Three & Nine Months
10 Nov 2022 //
BUSINESSWIRE
Revelation Announces Results in Model of Acute & Chronic Kidney Disease
25 Oct 2022 //
BUSINESSWIRE
Revelation Announces Financial Results for the 3 and 6 Months
15 Aug 2022 //
GLOBENEWSWIRE
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
29 Jul 2022 //
GLOBENEWSWIRE
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
26 Jul 2022 //
GLOBENEWSWIRE
Revelation Biosciences Shares Surge 87% Following REVTx-99b Study Disclosure
26 Jul 2022 //
MARKETWATCH
Revelation Bio Announces Topline Data for PIb CLEAR Study of REVTx-99b
22 Jul 2022 //
GLOBENEWSWIRE
Revelation Bio Completes Database Lock for its P1b CLEAR Study of REVTx-99b
14 Jul 2022 //
GLOBENEWSWIRE
Revelation Bio Completes Dosing for PIb Study of REVTx-99b for Allergic Rhinitis
13 Jun 2022 //
GLOBENEWSWIRE
Revelation Announces Safety Monitoring Committee Recommendation for REVTx-99b
23 May 2022 //
GLOBENEWSWIRE
Revelation Bio Announces Financial Results for 3 Months Ended March 31, 2022
16 May 2022 //
GLOBENEWSWIRE
Revelation Bio Announces Conference Call to Provide a Corporate Update
06 Apr 2022 //
GLOBENEWSWIRE
Revelation Bio Shows Primary Endpoint Analysis for Phase 2b Study of REVTx-99a
30 Mar 2022 //
GLOBENEWSWIRE
Revelation Bio Shows Details on Data Analysis for Phase 2b Viral Challenge Study
24 Mar 2022 //
GLOBENEWSWIRE
Revelation Bio to Present at 2022 Virtual Growth Conference by Maxim Group
22 Mar 2022 //
GLOBENEWSWIRE
Revelation Bio says Enrollment, Dosing Complete for PIIb Viral Study of REVTx 99
15 Mar 2022 //
GLOBENEWSWIRE
Revelation Bio Inc. to Present at the 34th Annual Roth Conference
08 Mar 2022 //
GLOBENEWSWIRE
Revelation Bio Begins Dosing in Phase 2b Study for Intranasal REVTx-99
20 Jan 2022 //
GLOBENEWSWIRE
Revelation Biosciences Begins Dosing in Phase 1b Study of REVTx-99
18 Jan 2022 //
GLOBENEWSWIRE
Revelation`s REVTx-99 data Demonstrates Anti-Viral Activity Against SARS-CoV-2
13 Jan 2022 //
GLOBENEWSWIRE
Revelation Bio Announces Data Demonstrating REVTx-99 In Vitro AntiViral Activity
11 Jan 2022 //
GLOBENEWSWIRE
Petra Acquisition, Announces Share Redemption Backstop and Forward
22 Dec 2021 //
GLOBENEWSWIRE
Revelation Biosciences begins Phase IIb trial of H3N2 influenza therapy
02 Dec 2021 //
CLINICALTRIALSARENA
Revelation Biosciences Inc. Announces Creation and Appointments
29 Nov 2021 //
GLOBENEWSWIRE
Revelation Announces Initiation of a Phase 1b Clinical Study of REVTx-99
15 Nov 2021 //
GLOBENEWSWIRE
Revelation Biosciences Engages Destum Partners to Identify Strategic Partners
25 Oct 2021 //
GLOBENEWSWIRE
Revelation Biosciences Inc. Receives Approval to Begin a Ph1b Study of REVTx-99
04 Oct 2021 //
GLOBENEWSWIRE
Revelation Biosciences Inc. Receives Approval to Begin a Ph1b Study of REVTx-99
04 Oct 2021 //
GLOBENEWSWIRE
Revelation Receives Approval to Initiate Ph2b Viral Challenge Study of REVTx 99
28 Sep 2021 //
GLOBENEWSWIRE
Revelation Biosciences Merges with SPAC Company to List on Nasdaq
31 Aug 2021 //
BIO SPACE
Revelation Become Publicly Traded Through a Merger with Petra Acquisition
30 Aug 2021 //
BUSINESSWIRE
Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference
09 Jun 2021 //
BUSINESSWIRE